Clinuvel Pharmaceuticals Limited (CLVLF)
USD 7.45
(0.0%)
USD 7.45
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 78.09 Million AUD | 12.32% |
| 2023 | 69.53 Million AUD | 25.88% |
| 2022 | 55.23 Million AUD | 27.7% |
| 2021 | 43.25 Million AUD | 88.59% |
| 2020 | 22.93 Million AUD | -5.13% |
| 2019 | 24.17 Million AUD | 23.98% |
| 2018 | 19.5 Million AUD | 53.94% |
| 2017 | 12.66 Million AUD | 411.49% |
| 2016 | 2.47 Million AUD | 702.49% |
| 2015 | 308.6 Thousand AUD | 129.18% |
| 2014 | -1.05 Million AUD | -176.29% |
| 2013 | 1.38 Million AUD | 91.83% |
| 2012 | 722.8 Thousand AUD | -30.57% |
| 2011 | 1.04 Million AUD | 0.0% |
| 2010 | - AUD | 100.0% |
| 2009 | -916.53 Thousand AUD | 3.06% |
| 2008 | -945.44 Thousand AUD | -40.3% |
| 2007 | -673.85 Thousand AUD | -189.27% |
| 2006 | 754.84 Thousand AUD | 505.71% |
| 2005 | 124.62 Thousand AUD | 0.0% |
| 2004 | - AUD | 0.0% |
| 2003 | - AUD | 0.0% |
| 2002 | - AUD | 0.0% |
| 2001 | - AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q4 | 40.99 Million AUD | 0.0% |
| 2024 FY | 78.09 Million AUD | 12.32% |
| 2024 Q1 | 15.17 Million AUD | -54.68% |
| 2024 Q2 | 16.92 Million AUD | 11.47% |
| 2023 Q2 | 20.92 Million AUD | 60.33% |
| 2023 FY | 69.53 Million AUD | 25.88% |
| 2023 Q1 | 13.05 Million AUD | -58.65% |
| 2023 Q3 | 22.34 Million AUD | 6.81% |
| 2023 Q4 | 33.49 Million AUD | 49.86% |
| 2022 Q1 | 9.79 Million AUD | -68.44% |
| 2022 FY | 55.23 Million AUD | 27.7% |
| 2022 Q4 | 31.56 Million AUD | 71.14% |
| 2022 Q3 | 18.44 Million AUD | 22.47% |
| 2022 Q2 | 15.05 Million AUD | 53.73% |
| 2021 Q2 | 14.85 Million AUD | 112.79% |
| 2021 Q4 | 31.03 Million AUD | 105.64% |
| 2021 Q3 | 15.09 Million AUD | 1.64% |
| 2021 Q1 | 6.97 Million AUD | -63.31% |
| 2021 FY | 43.25 Million AUD | 88.59% |
| 2020 Q4 | 19.01 Million AUD | 146.3% |
| 2020 FY | 22.93 Million AUD | -5.13% |
| 2020 Q1 | 4.91 Million AUD | -77.6% |
| 2020 Q2 | 9.89 Million AUD | 101.53% |
| 2020 Q3 | 7.72 Million AUD | -21.97% |
| 2019 Q2 | 4.4 Million AUD | 0.0% |
| 2019 Q3 | 10.89 Million AUD | 147.14% |
| 2019 FY | 24.17 Million AUD | 23.98% |
| 2019 Q1 | 4.4 Million AUD | -50.14% |
| 2019 Q4 | 21.92 Million AUD | 101.28% |
| 2018 Q3 | 8.84 Million AUD | 157.92% |
| 2018 Q4 | 8.84 Million AUD | 0.0% |
| 2018 Q2 | 3.42 Million AUD | 0.0% |
| 2018 FY | 19.5 Million AUD | 53.94% |
| 2018 Q1 | 3.42 Million AUD | -26.79% |
| 2017 Q2 | 3.39 Million AUD | 0.0% |
| 2017 Q1 | 3.39 Million AUD | 101.5% |
| 2017 Q4 | 4.68 Million AUD | 0.0% |
| 2017 FY | 12.66 Million AUD | 411.49% |
| 2017 Q3 | 4.68 Million AUD | 37.98% |
| 2016 Q1 | 757.94 Thousand AUD | 143.01% |
| 2016 FY | 2.47 Million AUD | 702.49% |
| 2016 Q4 | 1.68 Million AUD | 0.0% |
| 2016 Q3 | 1.68 Million AUD | 122.18% |
| 2016 Q2 | 757.94 Thousand AUD | 0.0% |
| 2015 Q2 | 466.89 Thousand AUD | 0.0% |
| 2015 Q3 | -1.76 Million AUD | -477.42% |
| 2015 FY | 308.6 Thousand AUD | 129.18% |
| 2015 Q4 | -1.76 Million AUD | 0.0% |
| 2015 Q1 | 466.89 Thousand AUD | -38.61% |
| 2014 FY | -1.05 Million AUD | -176.29% |
| 2014 Q4 | 760.49 Thousand AUD | 0.0% |
| 2014 Q1 | 384.98 Thousand AUD | -45.26% |
| 2014 Q2 | 384.98 Thousand AUD | -0.0% |
| 2014 Q3 | 760.49 Thousand AUD | 97.54% |
| 2013 FY | 1.38 Million AUD | 91.83% |
| 2013 Q3 | 703.25 Thousand AUD | 0.0% |
| 2013 Q4 | 703.25 Thousand AUD | 0.0% |
| 2012 FY | 722.8 Thousand AUD | -30.57% |
| 2011 FY | 1.04 Million AUD | 0.0% |
| 2010 FY | - AUD | 100.0% |
| 2009 FY | -916.53 Thousand AUD | 3.06% |
| 2008 FY | -945.44 Thousand AUD | -40.3% |
| 2007 FY | -673.85 Thousand AUD | -189.27% |
| 2006 FY | 754.84 Thousand AUD | 505.71% |
| 2005 FY | 124.62 Thousand AUD | 0.0% |
| 2004 FY | - AUD | 0.0% |
| 2003 FY | - AUD | 0.0% |
| 2002 FY | - AUD | 0.0% |
| 2001 FY | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 11.7 Million USD | -567.153% |
| BioStem Technologies, Inc. | 15.42 Million USD | -406.306% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 34.432% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 402.725% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -44132.5% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -55484.984% |
| Arch Therapeutics, Inc. | -2439.00 USD | 3202105.002% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 24542.939% |
| Qrons Inc. | - USD | -Infinity% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 62954.144% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 161928.679% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 98.967% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -712.578% |
| Adynxx, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -420.681% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -2517530.625% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | -697.395% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -118718.315% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 228787.854% |
| Mesoblast Limited | -35.16 Million USD | 322.068% |
| Marizyme, Inc. | 457.7 Thousand USD | -16962.827% |
| Genus plc | 178.7 Million USD | 56.297% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 64.518% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -125405.258% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -18940.362% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 710071.836% |
| ContraFect Corporation | -154 Thousand USD | 50812.274% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 156293.804% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -101640.339% |
| IMV Inc. | -962.29 Thousand USD | 8215.667% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 20253.987% |
| MultiCell Technologies, Inc. | 49.32 USD | -158347227.656% |
| ONE Bio Corp. | 20.12 Million USD | -288.051% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | -93.957% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -159607.366% |
| Q BioMed Inc. | -8988.00 USD | 869001.891% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -176.4% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 506433.649% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | -76.061% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 6941.172% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -111467.003% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 1577177.989% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 80187.066% |
| GB Sciences, Inc. | -624.00 USD | 12515629.167% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 90880.795% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 37546687.5% |
| Enzolytics Inc. | 30.7 Thousand USD | -254221.03% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -16088.134% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 92.955% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 15278.889% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -12549.648% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 80.931% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 881953.004% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 93239.932% |
| Kadimastem Ltd | -630.13 Thousand USD | 12493.619% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -7804.697% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 659980.879% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -44132.5% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -5654.508% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 269399.662% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -17253.209% |
| SYBLEU INC | 11.69 Thousand USD | -667623.17% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -1594.811% |
| Bioxytran, Inc. | -8285.00 USD | 942730.078% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 21037.507% |
| Neutra Corp. | 14.33 Thousand USD | -544698.758% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 95340.124% |
| PureTech Health plc | -1.6 Million USD | 4971.922% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 7900.049% |
| IXICO plc | 3.27 Million USD | -2288.284% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 11353.156% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 4460.519% |
| CSL Limited | 7.7 Billion USD | 98.986% |
| Cellectis S.A. | 18 Thousand USD | -433771.678% |